Navigation Links
Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program

FLINT, Mich., Jan. 17 /PRNewswire/ -- Diplomat Specialty Pharmacy, one of the largest privately owned national specialty pharmacies, announced today that it has entered into an agreement with Genzyme Corporation to administer their 2008 Renagel Medicare Part D Assistance Program. Genzyme is one the world's largest biotechnology companies dedicated to products and services focused in kidney disease, rare inherited disorders, orthopedics, transplant, and oncology.

Diplomat will be the 2008 national Part D Assistance provider for Renagel(R) (sevelamer hydrochloride). Renagel is a non-calcium/non-metal based phosphorus binder indicated for the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on dialysis. The Renagel Part D Assistance Program provides Renagel free of charge to patients who are enrolled in a Medicare Prescription Drug Plan but cannot afford their copayments or co-insurance payments for Renagel. The Renagel Part D Assistance program complements Diplomat's existing renal program which includes pharmacy delivery of required medications to dialysis patients and CKD disease management.

"Genzyme Corporation selected Diplomat Specialty Pharmacy to administer our 2008 Renagel Medicare Part D Assistance Program because of their understanding of the renal sector and reputation for providing a high level of customer service for over 30 years," stated Robin Goldwater, Director of Reimbursement & Specialty Services of Genzyme Corporation. "Our group will work closely with the Diplomat team to help qualified patients receive free Renagel.

"Diplomat is honored to be chosen as Genzyme's pharmacy partner for the 2008 Renagel Medicare Part D Assistance program," stated Phil Hagerman RPh, President/CEO of Diplomat Specialty Pharmacy. "Diplomat's experience and commitment to patients with Chronic Kidney Disease will help support Genzyme's premier national renal program that will assist dialysis patients to gain access to required medications and achieve optimal clinical outcomes."

Those interested in more information or in applying to the Program should contact Genzyme's Renassist Program at 1-800-847-0069.

About Diplomat Specialty Pharmacy

Diplomat Specialty Pharmacy is a privately held health care organization focusing on complete medication management programs for patients with serious and chronic conditions. Key programs include: Oncology, HIV/AIDS, Hepatitis C, Multiple Sclerosis, Rheumatoid Arthritis and Psoriasis. Other specialty areas include Transplant, Fertility, Dialysis Medication Management, Bio- Identical Hormone Replacement Therapy and Specialty Compounding. The company's Health Services division specializes in disease management programs for Chronic Kidney Disease patients, as well as home and outpatient infusion. With locations in Flint and Grand Rapids, MI; Cleveland, OH; Chicago, IL; and Ft. Lauderdale, Florida; Diplomat services the specialty pharmacy needs of patients and physicians nationwide.

For more information contact:

Kathy Karns


SOURCE Diplomat Specialty Pharmacy
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
2. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
3. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
4. CEL-SCI Corporation Announces 2007 Financial Results
5. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
6. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
7. Immunosyn Corporation Releases SF-1019 Study Results
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
9. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
10. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
11. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
Breaking Medicine Technology:
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
Breaking Medicine News(10 mins):